Morepen Laboratories Limited (BOM: 500288)
India
· Delayed Price · Currency is INR 87.56
-1.43 (-1.61%)
At close: Oct 11, 2024
Morepen Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 17,446 | 16,904 | 14,175 | 15,468 | 11,881 | 8,396 | Upgrade
|
| Other Revenue | 124.74 | 114.67 | 44.76 | 89.77 | 99.35 | 187.52 | Upgrade
|
| Revenue | 17,571 | 17,019 | 14,220 | 15,558 | 11,980 | 8,584 | Upgrade
|
| Revenue Growth (YoY) | 15.31% | 19.68% | -8.60% | 29.87% | 39.57% | 11.27% | Upgrade
|
| Cost of Revenue | 11,098 | 10,858 | 9,750 | 10,611 | 7,882 | 5,634 | Upgrade
|
| Gross Profit | 6,472 | 6,161 | 4,470 | 4,947 | 4,098 | 2,949 | Upgrade
|
| Selling, General & Admin | 1,998 | 1,935 | 1,654 | 1,724 | 1,407 | 1,143 | Upgrade
|
| Other Operating Expenses | 2,508 | 2,525 | 1,976 | 1,766 | 1,406 | 1,069 | Upgrade
|
| Operating Expenses | 4,821 | 4,795 | 3,910 | 3,767 | 3,116 | 2,580 | Upgrade
|
| Operating Income | 1,651 | 1,366 | 560.79 | 1,180 | 981.65 | 369.02 | Upgrade
|
| Interest Expense | -45.79 | -37.1 | -19.81 | -24.26 | -17.88 | -19.85 | Upgrade
|
| Interest & Investment Income | 25.04 | 25.04 | 16.57 | 13.3 | 21.34 | 41.96 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | 97.92 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 1,631 | 1,354 | 557.55 | 1,267 | 985.12 | 391.13 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -0.06 | Upgrade
|
| Pretax Income | 1,631 | 1,354 | 557.55 | 1,267 | 985.12 | 391.08 | Upgrade
|
| Income Tax Expense | 449.15 | 387.95 | 170.8 | 250.21 | 14.22 | 55.29 | Upgrade
|
| Earnings From Continuing Operations | 1,182 | 966.2 | 386.76 | 1,017 | 970.9 | 335.79 | Upgrade
|
| Minority Interest in Earnings | -4.61 | -4.6 | -0 | 0.01 | -0.04 | 0 | Upgrade
|
| Net Income | 1,177 | 961.6 | 386.75 | 1,017 | 970.86 | 335.79 | Upgrade
|
| Net Income to Common | 1,177 | 961.6 | 386.75 | 1,017 | 970.86 | 335.79 | Upgrade
|
| Net Income Growth | 146.85% | 148.63% | -61.96% | 4.73% | 189.13% | 16.40% | Upgrade
|
| Shares Outstanding (Basic) | 512 | 511 | 502 | 450 | 450 | 450 | Upgrade
|
| Shares Outstanding (Diluted) | 512 | 511 | 502 | 520 | 451 | 450 | Upgrade
|
| Shares Change (YoY) | 0.24% | 1.78% | -3.39% | 15.24% | 0.28% | - | Upgrade
|
| EPS (Basic) | 2.30 | 1.88 | 0.77 | 2.26 | 2.16 | 0.75 | Upgrade
|
| EPS (Diluted) | 2.30 | 1.88 | 0.77 | 1.96 | 2.15 | 0.75 | Upgrade
|
| EPS Growth | 146.13% | 144.16% | -60.71% | -8.84% | 188.01% | 16.64% | Upgrade
|
| Free Cash Flow | - | 19.94 | -1,268 | -1,057 | 290.26 | -56.46 | Upgrade
|
| Free Cash Flow Per Share | - | 0.04 | -2.52 | -2.03 | 0.64 | -0.13 | Upgrade
|
| Gross Margin | 36.84% | 36.20% | 31.44% | 31.80% | 34.20% | 34.36% | Upgrade
|
| Operating Margin | 9.40% | 8.03% | 3.94% | 7.58% | 8.19% | 4.30% | Upgrade
|
| Profit Margin | 6.70% | 5.65% | 2.72% | 6.54% | 8.10% | 3.91% | Upgrade
|
| Free Cash Flow Margin | - | 0.12% | -8.92% | -6.79% | 2.42% | -0.66% | Upgrade
|
| EBITDA | 1,805 | 1,545 | 840.09 | 1,456 | 1,284 | 738.02 | Upgrade
|
| EBITDA Margin | 10.27% | 9.08% | 5.91% | 9.36% | 10.72% | 8.60% | Upgrade
|
| D&A For EBITDA | 153.6 | 178.74 | 279.3 | 276.43 | 302.83 | 369 | Upgrade
|
| EBIT | 1,651 | 1,366 | 560.79 | 1,180 | 981.65 | 369.02 | Upgrade
|
| EBIT Margin | 9.40% | 8.03% | 3.94% | 7.58% | 8.19% | 4.30% | Upgrade
|
| Effective Tax Rate | 27.54% | 28.65% | 30.63% | 19.75% | 1.44% | 14.14% | Upgrade
|
| Revenue as Reported | 17,596 | 17,044 | 14,237 | 15,571 | 12,001 | 8,626 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.